[HTML][HTML] Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms

Q Han, B Zheng, L Daines, A Sheikh - Pathogens, 2022 - mdpi.com
Emerging evidence has shown that COVID-19 survivors could suffer from persistent
symptoms. However, it remains unclear whether these symptoms persist over the longer …

13. Older Adults: Standards of Care in Diabetes—2023

NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Beyond the imitation game: Quantifying and extrapolating the capabilities of language models

A Srivastava, A Rastogi, A Rao, AAM Shoeb… - arXiv preprint arXiv …, 2022 - arxiv.org
Language models demonstrate both quantitative improvement and new qualitative
capabilities with increasing scale. Despite their potentially transformative impact, these new …

Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial

MM Gonzales, VR Garbarino, TF Kautz, JP Palavicini… - Nature medicine, 2023 - nature.com
Cellular senescence contributes to Alzheimer's disease (AD) pathogenesis. An open-label,
proof-of-concept, phase I clinical trial of orally delivered senolytic therapy, dasatinib (D) and …

[HTML][HTML] Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study

RA Evans, H McAuley, EM Harrison… - The Lancet …, 2021 - thelancet.com
Background The impact of COVID-19 on physical and mental health and employment after
hospitalisation with acute disease is not well understood. The aim of this study was to …

[HTML][HTML] Trial of the MIND diet for prevention of cognitive decline in older persons

LL Barnes, K Dhana, X Liu, VJ Carey… - … England Journal of …, 2023 - Mass Medical Soc
Background Findings from observational studies suggest that dietary patterns may offer
protective benefits against cognitive decline, but data from clinical trials are limited. The …

Trial of lixisenatide in early Parkinson's disease

WG Meissner, P Remy, C Giordana… - … England Journal of …, 2024 - Mass Medical Soc
Background Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment
of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease …

[HTML][HTML] Parkinson disease-associated cognitive impairment

D Aarsland, L Batzu, GM Halliday… - Nature Reviews …, 2021 - nature.com
Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

[HTML][HTML] Trial of deferiprone in Parkinson's disease

D Devos, J Labreuche, O Rascol… - … England Journal of …, 2022 - Mass Medical Soc
Background Iron content is increased in the substantia nigra of persons with Parkinson's
disease and may contribute to the pathophysiology of the disorder. Early research suggests …

European resuscitation council and European society of intensive care medicine guidelines 2021: post-resuscitation care

JP Nolan, C Sandroni, BW Böttiger, A Cariou… - Resuscitation, 2021 - Elsevier
Abstract The European Resuscitation Council (ERC) and the European Society of Intensive
Care Medicine (ESICM) have collaborated to produce these post-resuscitation care …